Close Menu

NEW YORK (GenomeWeb) – Invitae announced today that it has completed its acquisition of CombiMatrix.

With the closing of the deal, Invitae issued approximately $21.2 million in shares of its own common stock, about 2.7 million shares, to former CombiMatrix shareholders. Combined with the approximately 1.7 million shares of Invitae common stock underlying CombiMatrix Series F warrants assumed in the acquisition, the transaction has a total enterprise value of approximately $34.9 million, Invitae said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

In Nature this week: a new method for high-throughput amplicon sequencing, and more.